AAAAAA
Results:
1-13
|
Results: 13
Authors:
Adenis, A
Bonneterre, J
Bonneterre, ME
Pion, JM
Vanlemmens, L
Gladieff, L
de Lafontan, B
Martel, P
Mihura, J
Roche, H
Gedouin, D
Kerbrat, P
Lesimple, T
Bremond, A
Devaux, Y
Delecroix, V
Fumoleau, P
Maugard-Louboutin, C
Namer, M
Goudier, MJ
Morice, F
Montcuquet, P
Schraub, S
Coudert, B
Fargeot, P
de Gislain, C
Mayer, F
Bastit, P
Chevallier, B
Grandgirard, A
Monnier, A
Sun, X
Clavere, P
Ollivier, JP
Rhein, B
Roullet, B
Datchary, J
Audhuy, B
Barats, JC
Kohser, F
Dides, S
Ramos, R
Cattan, A
Eymard, JC
Pourny, C
Weber, B
de Laroche, G
Pichon, A
Seffert, P
Hayat, M
Zambon, E
Chollet, P
Van Praagh, I
Citation: A. Adenis et al., Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French adjuvant study group 05 randomized trial, J CL ONCOL, 19(3), 2001, pp. 602-611
Authors:
Isambert, N
Correia, M
Cercueil, JP
Zanetta, S
Osmak, L
Flesch, M
Krause, D
Coudert, B
Fargeot, P
Bedenne, L
Chauffert, B
Citation: N. Isambert et al., Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucosesolution administered in balloon-occluded hepatic artery: Experimental rationale and clinical pilot study, J EXP CL C, 20(2), 2001, pp. 183-188
Authors:
Bastian, G
Seitz, JF
Moutardier, V
Delperro, JR
Fargeot, P
Fraisse, J
Formento, P
Chazard, M
Renee, N
Milano, G
Citation: G. Bastian et al., Impact of UFT on tumoral TS and DPD levels in colorectal cancer, ONCOLOGY-NY, 14(10), 2000, pp. 35-37
Authors:
Fumoleau, P
Deporte, R
Kerbrat, P
Bonneterre, J
Fargeot, P
Citation: P. Fumoleau et al., UFT/leucovorin plus vinorelbine combination for advanced breast cancer, ONCOLOGY-NY, 14(10), 2000, pp. 50-55
Authors:
Bastit, P
Chevallier, B
Chevreau, C
Mihura, J
Roche, H
Namer, M
Gedouin, D
Kerbrat, P
Lesimple, T
Coudert, B
Fargeot, P
de Gislain, C
Mayer, F
Luporsi, E
Rios, M
Weber, B
Bremond, A
Devaux, Y
Monteuquet, P
Schraub, S
Hayat, M
Zambon, E
Grandgirard, A
Monnier, A
Sun, X
Clavere, P
Ollivier, JP
Rhein, B
Roullet, B
Chollet, P
Van Praagh, I
Cattan, A
Eymard, JC
Pourny, C
Facchini, T
Walter, S
Dides, S
Ramos, R
Guiochet, N
Seffert, P
Perpoint, X
Sztermer, JF
Cretin, J
Goudier, MJ
Morice, F
Delecroix, V
Fumoleau, P
Citation: P. Bastit et al., Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment, J CL ONCOL, 18(17), 2000, pp. 3115-3124
Authors:
Ellmen, J
Werner, D
Hakulinen, P
Keiling, R
Fargeot, P
Falkson, G
Bezwoda, WR
Citation: J. Ellmen et al., Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients, CANC CHEMOT, 45(5), 2000, pp. 402-408
Authors:
Arnould, L
Jouannelle, C
Mege, F
Maillefert, F
Fargeot, P
Devillebichot, C
Collin, F
Citation: L. Arnould et al., Sclerosing epithelioid fibrosarcoma: a fibrosarcoma with a very long course, ANN PATHOL, 20(2), 2000, pp. 154-157
Authors:
Laplanche, A
Alzieu, L
Delozier, T
Berlie, J
Veyret, C
Fargeot, P
Luboinski, M
Lacour, J
Citation: A. Laplanche et al., Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: A 14 year follow-up analysis ofa randomized trial of the Federation Nationale des Centres de Lutte Contrele Cancer (FNCLCC), BREAST CANC, 64(2), 2000, pp. 189-191
Authors:
Arnal, M
Franco, N
Fargeot, P
Riedinger, JM
Brunet-Lecomte, P
Lizard-Nacol, S
Citation: M. Arnal et al., Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer, BREAST CANC, 61(1), 2000, pp. 13-20
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults
Authors:
Roche, H
Cure, H
Adenis, A
Fargeot, P
Terret, C
Lentz, MA
Madelmont, JC
Fumoleau, P
Hanauske, A
Chollet, P
Citation: H. Roche et al., Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults, J NEURO-ONC, 49(2), 2000, pp. 141-145
Authors:
Cure, H
Souteyrand, P
Ouabdesselam, R
Roche, H
Ravaud, A
D'incan, M
Viens, P
Fargeot, P
Lentz, MA
Fumoleau, P
Hanauske, A
Chollet, P
Citation: H. Cure et al., Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- orsecond-line treatment in advanced malignant melanoma: a trial of the EORTCClinical Studies Group, MELANOMA RE, 9(6), 1999, pp. 607-610
Authors:
Lhomme, C
Fumoleau, P
Fargeot, P
Krakowski, Y
Dieras, V
Chauvergne, J
Vennin, P
Rebattu, P
Roche, H
Misset, JL
Lentz, MA
Van Glabbeke, M
Matthieu-Boue, A
Mignard, D
Chevallier, B
Citation: C. Lhomme et al., Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix, J CL ONCOL, 17(10), 1999, pp. 3136-3142
Authors:
Lizard-Nacol, S
Genne, P
Coudert, B
Riedinger, JA
Arnal, M
Sancy, C
Brunet-Lecomte, P
Fargeot, P
Citation: S. Lizard-nacol et al., MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: Relationships to drug exposure, p53 mutations, and clinical outcome ofthe patients, ANTICANC R, 19(4C), 1999, pp. 3575-3581
Risultati:
1-13
|